Contact

Insulin Degludec has been approved by the National Medical Products Administration(NMPA) for clinical trials

Published Date: Mar 11 2022


Gene-Biocon has received the "Notice of Approval for Clinical Trials of Insulin Degludec Injection" issued by the State Drug Administration

*Acceptance number: [CXSL2101500]


As one of the leading biopharmaceutical biopharma companies in China, Gene-Biocon has remained true to our original aspiration and escorted customers with continuous innovation. In the future, Gene-Biocon will continue to devote itself to the field of Biopharmaceutical raw materials and cosmetic raw materials, and continue to produce with high-quality and safe products for our customers.



Products

Related Biological Products
What's New At Gene-Biocon
All products from the site for Research Use Only. Not for use in diagnostic procedures. Reproduction of any materials is strictly forbidden without permission.
We use cookies on this site, including third party cookies, to deliver experience for you.
Accept Cookies
Read Privacy Policy
Contact
Email: inquiry@g-biotec.com Tel:+86-756-6348118
Address:
11th Floor, Building 4, No. 628 Airport West Road, Zhuhai, GuangDong, China
Career Partner Program
All products from the site for Research Use Only. Not for use in diagnostic procedures. Reproduction of any materials is strictly forbidden without permission.